V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007261 | 10005110 | 1.59 | 66 | Palliative (P) | 2018-05-16 | 2018-05-16 | PERTUZUMAB + TRASTUZUMAB | 02 | N | 10520720 | DOCETAXEL + TRASTUZUMAB |
| 10007262 | 10005111 | 1.68 | 65.8 | Curative (C) | 2017-08-27 | 2017-08-27 | CISPLATIN + GEMCITABINE | 02 | N | 10521051 | CYTARABINE HIGH DOSE |
| 10007263 | 10005112 | 1.55 | 112.8 | Curative (C) | 2017-02-13 | 2017-04-26 | Capecitabine + Cisplatin + RT | 2 | N | 10521122 | CISPLATIN + PEMETREXED |
| 10007264 | 10005112 | 1.64 | 42.7 | Disease modification (D) | 2016-02-02 | 2016-02-05 | DABRAFENIB | 02 | N | 10521122 | MCX |
| 10007265 | 10008612 | 1.9 | 92.5 | Palliative (P) | 2014-04-08 | 2014-04-15 | Cytarabine intrathecal | 02 | N | 10521664 | CISPLATIN + ETOPOSIDE |
| 10007266 | 10005113 | 1.8 | 71 | Palliative (P) | 2015-07-14 | 2015-08-13 | Enzalutamide | N | Y | 10521703 | ARSENIC TRIOXIDE + TRETINOIN |
| 10007267 | 10005114 | 1.87 | 76.8 | Curative (C) | 2015-07-10 | 2015-07-11 | R CODOX-M/ R IVAC | 02 | N | 10521703 | DOCETAXEL + NINTEDANIB |
| 10007268 | 10005114 | 1.58 | 65 | Adjuvant (A) | 2017-08-09 | 2017-08-12 | Cisplatin + Pemetrexed | 2 | N | 10521703 | ECX |
| 10007269 | 10005116 | 1.64 | 71.6 | Palliative (P) | null | 2017-09-10 | CYCLOPHOSPHAMIDE + MITOXANTRONE + RITUXIMAB + VINCRISTINE | 02 | N | 10521975 | LOMUSTINE + PROCARBAZINE |
| 10007270 | 10005118 | 1.65 | 55.4 | Curative (C) | 2016-08-13 | 2016-08-15 | Cisplatin + Pemetrexed | N | Y | 10522696 | NINTEDANIB |
| 10007271 | 10005118 | null | null | Not known (9) | 2016-07-30 | 2016-08-07 | GEM-P | null | N | 10522696 | VEDEX |
| 10007272 | 10005118 | 1.74 | 99.4 | Neo-adjuvant (N) | 2013-12-11 | 2013-12-12 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | 10522696 | BENDAMUSTINE + OBINUTUZUMAB |
| 10007273 | 10005119 | 1.73 | null | Curative (C) | 2018-07-20 | 2018-07-25 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10524099 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10007274 | 10005120 | null | 59.8 | Curative (C) | 2018-03-30 | 2018-04-30 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 10524278 | DOCETAXEL + NINTEDANIB |
| 10007275 | 10005121 | 1.82 | 82 | null | 2016-03-01 | 2016-03-28 | Methotrexate intrathecal | N | N | 10524321 | CISPLATIN + GEMCITABINE |
| 10007276 | 10005122 | 1.85 | 85.8 | Neo-adjuvant (N) | 2017-04-21 | 2017-04-21 | Vincristine (weekly) | 02 | N | 10524321 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE |
| 10007277 | 10005123 | 1.86 | 71 | Adjuvant (A) | 2017-06-06 | 2017-06-08 | CARBOPLATIN + PACLITAXEL + RT | N | N | 10524525 | TRIFLURIDINE + TIPIRACIL |
| 10007278 | 10005124 | 1.77 | 76.8 | Disease modification (D) | 2018-03-05 | 2018-03-24 | Cytarabine HD + Rituximab | N | N | 10524789 | BORTEZOMIB + PANOBINOSTAT |
| 10007279 | 10005126 | 1.78 | 82.3 | Palliative (P) | 2016-01-22 | 2016-07-20 | Bortezomib + Panobinostat | N | Y | 10525059 | CISPLATIN + ETOPOSIDE |
| 10007280 | 10005128 | 1.71 | null | Curative (C) | 2017-08-25 | 2017-09-15 | Chlorambucil + Pred + Rituximab | 02 | N | 10525059 | REMODL TRIAL |
| 10007281 | 10005128 | null | 62.8 | Curative (C) | 2017-11-29 | 2017-12-15 | Cyclophosphamide High Dose | N | N | 10525059 | ENZALUTAMIDE |
| 10007282 | 10005129 | 1.62 | 91 | null | 2016-04-16 | 2016-06-11 | AML16 Azacitidine | N | N | 10525819 | CISPLATIN + FLUOROURACIL |
| 10007283 | 10005131 | 1.79 | 68 | Palliative (P) | 2015-10-05 | 2015-10-06 | R ABVD | 2 | N | 10526569 | CETUXIMAB + IRINOTECAN + MDG |
| 10007284 | 10005132 | null | 54.9 | Palliative (P) | 2016-02-23 | 2016-02-24 | TAC | N | N | 10526597 | RUXOLITINIB |
| 10007285 | 10005133 | null | null | Disease modification (D) | 2017-10-17 | 2017-10-27 | Vincristine (weekly) | N | null | 10526752 | EOX |
| 10007286 | 10005136 | 1.6 | null | Adjuvant (A) | 2017-12-31 | 2018-01-21 | VINORELBINE | N | N | 10526926 | CISPLATIN + FLUOROURACIL |
| 10007287 | 10005138 | 1.83 | 64.7 | Disease modification (D) | 2016-12-11 | 2016-12-14 | MPV (cycle 5-9) - maintenance | N | N | 10526987 | IMATINIB |
| 10007288 | 10005141 | 1.53 | 60.4 | null | null | 2016-12-30 | DHAP | 2 | N | 10527021 | LIPOSOMAL DOXORUBICIN |
| 10007289 | 10005143 | 1.81 | 99.4 | Disease modification (D) | 2017-08-31 | 2017-09-07 | Pazopanib | 02 | N | 10527021 | R IVAC |
| 10007290 | 10005144 | 1.73 | null | null | 2017-11-01 | 2017-11-03 | GDP | N | N | 10527298 | CISPLATIN + ETOPOSIDE |
| 10007291 | 10005145 | 0 | 100 | Adjuvant (A) | 2018-10-05 | 2018-10-06 | AML 18 TRIAL | N | N | 10527424 | EOX |
| 10007292 | 10005145 | 1.74 | 63 | Palliative (P) | 2018-05-25 | 2018-05-28 | Erlotinib | 2 | N | 10527424 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 10007293 | 10005146 | 1.87 | 65 | Adjuvant (A) | 2015-03-08 | 2015-04-03 | CARBOPLATIN + GEMCITABINE + RITUXIMAB | N | N | 10527747 | PAZOPANIB |
| 10007294 | 10005147 | 1.54 | 71 | Palliative (P) | 2019-03-31 | 2019-03-31 | CHOP | 02 | N | 10527747 | VEDEX |
| 10007295 | 10005148 | 1.64 | 77.3 | Palliative (P) | null | 2018-05-23 | MPV (cycle 1-4) | N | N | 10527906 | CHLORAMBUCIL + RITUXIMAB |
| 10007296 | 10005150 | 1.73 | 65 | Curative (C) | 2018-01-28 | 2018-03-18 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 10528303 | CISPLATIN + RT |
| 10007297 | 10005151 | 1.75 | 70.6 | Neo-adjuvant (N) | 2015-11-13 | 2015-12-11 | Carboplatin + Liposomal Doxorubicin | N | Y | 10529167 | DABRAFENIB |
| 10007298 | 10005151 | 1.74 | 80.6 | Adjuvant (A) | 2016-01-31 | 2016-10-25 | Melphalan oral | 2 | Y | 10529167 | CRIZOTINIB |
| 10007299 | 10005151 | 1.8 | 86 | Curative (C) | 2018-03-25 | 2018-03-26 | OXALIPLATIN | 02 | N | 10529167 | BORTEZOMIB |
| 10007300 | 10005151 | 1.63 | 63.7 | Neo-adjuvant (N) | 2016-08-27 | 2016-09-10 | Cyclophosphamide High Dose | 02 | N | 10529167 | CETUXIMAB + OXALIPLATIN + MDG |
| 10007301 | 10005152 | 1.79 | null | Neo-adjuvant (N) | 2018-08-14 | 2018-08-14 | Docetaxel + Nintedanib | null | N | 10530622 | ERLOTINIB |
| 10007302 | 10007576 | 1.78 | 80 | Adjuvant (A) | 2015-04-15 | 2015-04-24 | NIVOLUMAB | 02 | Y | 10530690 | MELPHALAN |
| 10007303 | 10005154 | 0 | 65 | Disease modification (D) | 2014-12-25 | 2015-04-21 | Ipilimumab | 2 | Y | 10530690 | LENALIDOMIDE + RITUXIMAB |
| 10007304 | 10008620 | 1.75 | 63.5 | Neo-adjuvant (N) | null | 2019-01-28 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | Y | 10530752 | DOCETAXEL + NINTEDANIB |
| 10007305 | 10008620 | 1.76 | 71.1 | Palliative (P) | 2016-11-03 | 2016-11-04 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | N | N | 10530752 | BORTEZOMIB + PANOBINOSTAT |
| 10007306 | 10008620 | 1.85 | 63.8 | Neo-adjuvant (N) | 2018-03-23 | 2018-03-26 | Mini BEAM | 02 | N | 10530752 | GEMCITABINE + OXALIPLATIN + RITUXIMAB |
| 10007307 | 10005156 | 1.68 | 69.5 | Disease modification (D) | 2019-04-23 | 2019-04-23 | IVAC | N | N | 10531378 | CAP + RT |
| 10007308 | 10005157 | 1.67 | 101.4 | Palliative (P) | 2019-05-15 | 2019-06-07 | NIVOLUMAB | N | N | 10531615 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10007309 | 10005160 | 0 | 58.1 | Curative (C) | 2017-03-11 | 2017-03-12 | VEDex | 2 | N | 10531661 | BORTEZOMIB |
| 10007310 | 10005161 | null | 79.6 | Curative (C) | 2017-04-13 | 2017-04-19 | AFATINIB | N | N | 10531672 | CETUXIMAB + IRINOTECAN + MDG |